Tea tree oil gel for mild to moderate acne; a 12 week uncontrolled, open-label phase II pilot study

被引:30
|
作者
Malhi, Harsimran Kaur [1 ]
Tu, Jenny [2 ]
Riley, Thomas V. [3 ,4 ,5 ]
Kumarasinghe, Sujith Prasad [2 ,5 ]
Hammer, Katherine A. [4 ]
机构
[1] St John God Hosp, Dept Gen Med, Perth, WA, Australia
[2] Royal Perth Hosp, Dept Dermatol, Perth, WA, Australia
[3] Queen Elizabeth II Med Ctr, PathWest Lab Med WA, Perth, WA, Australia
[4] Univ Western Australia, Sch Pathol & Lab Med M504, Perth, WA, Australia
[5] Hollywood Med Ctr, Perth, WA, Australia
关键词
alternative treatment; essential oil; in vivo efficacy; terpenes; propionibacterium; topical therapy; ADAPALENE-BENZOYL PEROXIDE; FIXED-DOSE COMBINATION; DOUBLE-BLIND; TOPICAL TREATMENT; VULGARIS; CLINDAMYCIN; MULTICENTER; EFFICACY; TOLERABILITY; 5-PERCENT;
D O I
10.1111/ajd.12465
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BackgroundThe efficacy, tolerability and acceptability of a tea tree oil gel (200 mg/g) and face wash (7 mg/g) were evaluated for the treatment of mild to moderate facial acne. MethodsIn this open-label, uncontrolled phase II pilot study, participants applied tea tree oil products to the face twice daily for 12 weeks and were assessed after 4, 8 and 12 weeks. Efficacy was determined from total numbers of facial acne lesions and the investigator global assessment (IGA) score. Tolerability was evaluated by the frequency of adverse events and the mean tolerability score determined at each visit. Product acceptability was assessed via a questionnaire at the end of the study period. ResultsAltogether 18 participants were enrolled, of whom 14 completed the study. Mean total lesion counts were 23.7 at baseline, 17.2 at 4, 15.1 at 8 and 10.7 at 12 weeks. Total lesion counts differed significantly over time by repeated measures anova (P < 0.0001). The mean IGA score was 2.4 at baseline, 2.2 at 4, 2.0 at 8 and 1.9 at 12 weeks, which also differed significantly over time (P = 0.0094). No serious adverse events occurred and minor local tolerability events were limited to peeling, dryness and scaling, all of which resolved without intervention. ConclusionThis study shows that the use of the tea tree oil products significantly improved mild to moderate acne and that the products were well tolerated.
引用
收藏
页码:205 / 210
页数:6
相关论文
共 50 条
  • [32] Donepezil Combined with Natural Hirudin Improves the Clinical Symptoms of Patients with Mild-to-Moderate Alzheimer's Disease: A 20-Week Open-Label Pilot Study
    Li, De-qiang
    Zhou, Yu-ping
    Yang, Han
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2012, 9 (03): : 248 - 255
  • [33] A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease
    Reisberg, B
    Doody, R
    Stöffler, A
    Schmitt, F
    Ferris, S
    Möbius, HJ
    ARCHIVES OF NEUROLOGY, 2006, 63 (01) : 49 - 54
  • [34] A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study
    Sarbagili-Shabat, Chen
    Albenberg, Lindsey
    Van Limbergen, Johan
    Pressman, Naomi
    Otley, Anthony
    Yaakov, Michal
    Wine, Eytan
    Weiner, Dror
    Levine, Arie
    NUTRIENTS, 2021, 13 (11)
  • [35] A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis
    Bowlus, Christopher L.
    Galambos, Michael R.
    Aspinall, Richard J.
    Hirschfield, Gideon M.
    Jones, David E. J.
    Doerffel, Yvonne
    Gordon, Stuart C.
    Harrison, Stephen A.
    Kremer, Andreas E.
    Mayo, Marlyn J.
    Thuluvath, Paul J.
    Levy, Cynthia
    Swain, Mark G.
    Neff, Guy W.
    Sheridan, David A.
    Stanca, Carmen M.
    Berg, Christoph P.
    Goel, Aparna
    Shiffman, Mitchell L.
    Vierling, John M.
    Boudes, Pol
    Steinberg, Alexandra
    Choi, Yun-Jung
    McWherter, Charles A.
    JOURNAL OF HEPATOLOGY, 2022, 77 (02) : 353 - 364
  • [36] Pilot study evaluating treatment with sumatriptan for moderate to severe post-traumatic headache: A phase 2 open-label study
    Sharma, Tara L.
    Lucas, Sylvia
    Barber, Jason
    Hoffman, Jeanne M.
    HEADACHE, 2024, 64 (09): : 1135 - 1142
  • [37] Tazarotene 0.1% gel for refractory mycosis fungoides lesions: An open-label pilot study
    Apisarnthanarax, N
    Talpur, R
    Ward, S
    Ni, X
    Kim, HW
    Duvic, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (04) : 600 - 607
  • [38] Ingenol mebutate gel for the treatment of molluscum contagiosum: An open-label comparative pilot study
    Shin, Kihyuk
    Bae, Kyung-Nam
    Kim, Hoon-Soo
    Kim, Byung-Soo
    Kim, Moon-Bum
    Ko, Hyun-Chang
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (01) : 254 - 255
  • [39] An Open-Label Pilot Study of Naftifine 1% Gel in the Treatment of Seborrheic Dermatitis of the Scalp
    Gold, Michael H.
    Bridges, Tancy
    Avakian, Edward V.
    Plaum, Stefan
    Fleischer, Alan B., Jr.
    Hardas, Bhushan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2012, 11 (04) : 514 - 518
  • [40] Acetyl-L-Carnitine Augmentation of Clozapine in Partial-Responder Schizophrenia: A 12-Week, Open-Label Uncontrolled Preliminary Study
    Bruno, Antonio
    Pandolfo, Gianluca
    Crucitti, Manuela
    Lorusso, Simona
    Zoccali, Rocco Antonio
    Muscatello, Maria Rosaria Anna
    CLINICAL NEUROPHARMACOLOGY, 2016, 39 (06) : 277 - 280